Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi PharmaTech Triples Earnings in Q3

publication date: Nov 13, 2007
WuXi PharmaTech, the Shanghai CRO that conforms to western standards, announced sharply higher Q3 results. On a year-over-year basis, revenues jumped 78% to $34 million while earnings were up 205% to $8.6 million. On a per-share basis, WuXi earned 12 cents, fully diluted. Although the Q3 report was solid and right on target, it did not inspire buying on the part of the investors, who decided to sell the news. WuXi opened today’s trading down almost 10% in the low $28 range. In mid-session, the stock had cut the loss in half, trading at $29.36, a drop of $1.55 or 5%. More details...

Stock Symbol: (NYSE: WX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here